FT819
FT819-102
Phase 1 small_molecule active
Quick answer
FT819 for Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) is a Phase 1 program (small_molecule) at FATE THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- FATE THERAPEUTICS INC
- Indication
- Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active